Alzai Health Corp. Completes Initial Public Offering

Alzai Health Corp. has successfully completed its initial public offering (IPO), raising aggregate gross proceeds of $4,050,000. The offering consisted of 10,125,000 units priced at $0.40 each, including 125,000 units sold through the exercise of an over-allotment option. Each unit comprises one common share and one-half of a common share purchase warrant, with the warrants exercisable at $0.60 until June 9, 2028. The offering was facilitated by Haywood Securities Inc., which acted as the exclusive agent.

Alzai Health Corp., based in Vancouver, British Columbia, operates in the health technology sector, focusing on innovative solutions for Alzheimer’s Disease and related dementias. The company has developed an artificial intelligence-driven, non-invasive risk screening solution that leverages existing patient data from routine clinical records. This technology aims to address a significant gap in the early identification of cognitive decline, as approximately 80% of Alzheimer's patients are diagnosed only in the later stages of the disease. By enabling earlier diagnosis and intervention, Alzai seeks to improve patient outcomes and support efficient disease management across various healthcare stakeholders.

The strategic rationale behind the IPO is to secure funding for Alzai's ongoing research and development efforts, as well as to enhance its sales and marketing initiatives. The net proceeds from the offering will also contribute to general working capital, positioning the company for future growth and expansion in the health technology landscape. With the increasing prevalence of Alzheimer’s Disease and the growing demand for early detection solutions, Alzai is well-positioned to capitalize on market opportunities.

The successful IPO comes at a time when the health technology sector is experiencing significant growth, driven by advancements in artificial intelligence and a heightened focus on preventive care. Investors are increasingly recognizing the potential of companies like Alzai that offer innovative solutions to pressing healthcare challenges. As the company’s common shares resume trading on the TSX Venture Exchange under the symbol “ALZI,” market participants will be closely monitoring its performance and the impact of its technology on the healthcare ecosystem.

Overall, Alzai Health Corp.'s IPO underscores the robust interest in health technology investments and the potential for innovative solutions to reshape patient care. As the company leverages its new capital to enhance its offerings, it may contribute to the broader trend of integrating technology into healthcare, ultimately benefiting patients and providers alike. The successful execution of this IPO may also encourage other health technology firms to consider similar pathways to access capital for growth and innovation.